These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
638 related articles for article (PubMed ID: 32577940)
1. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. Ham A; Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J Breast Cancer Res Treat; 2020 Aug; 183(1):107-116. PubMed ID: 32577940 [TBL] [Abstract][Full Text] [Related]
2. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798 [TBL] [Abstract][Full Text] [Related]
3. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881 [TBL] [Abstract][Full Text] [Related]
4. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M; N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871 [TBL] [Abstract][Full Text] [Related]
6. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278 [TBL] [Abstract][Full Text] [Related]
7. Palbociclib and Letrozole in Advanced Breast Cancer. Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747 [TBL] [Abstract][Full Text] [Related]
9. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500 [TBL] [Abstract][Full Text] [Related]
10. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671 [TBL] [Abstract][Full Text] [Related]
11. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388 [TBL] [Abstract][Full Text] [Related]
12. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785 [TBL] [Abstract][Full Text] [Related]
13. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366 [TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. Cersosimo RJ Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120 [TBL] [Abstract][Full Text] [Related]
15. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ Ann Oncol; 2019 Sep; 30(9):1514-1520. PubMed ID: 31250880 [TBL] [Abstract][Full Text] [Related]
16. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233 [TBL] [Abstract][Full Text] [Related]
17. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344 [TBL] [Abstract][Full Text] [Related]
18. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534 [TBL] [Abstract][Full Text] [Related]
19. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Mukai H; Shimizu C; Masuda N; Ohtani S; Ohno S; Takahashi M; Yamamoto Y; Nishimura R; Sato N; Ohsumi S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Lu DR; Toi M Int J Clin Oncol; 2019 Mar; 24(3):274-287. PubMed ID: 30515674 [TBL] [Abstract][Full Text] [Related]
20. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. Diéras V; Rugo HS; Schnell P; Gelmon K; Cristofanilli M; Loi S; Colleoni M; Lu DR; Mori A; Gauthier E; Huang Bartlett C; Slamon DJ; Turner NC; Finn RS J Natl Cancer Inst; 2019 Apr; 111(4):419-430. PubMed ID: 30032196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]